697 related articles for article (PubMed ID: 16337482)
21. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.
Muhlethaler-Mottet A; Otten LA; Steimle V; Mach B
EMBO J; 1997 May; 16(10):2851-60. PubMed ID: 9184229
[TBL] [Abstract][Full Text] [Related]
22. Type III bare lymphocyte syndrome: lack of HLA class II gene expression and reduction in HLA class I gene expression.
Sabatier C; Gimenez C; Calin-Laurens V; Rabourdin-Combe C; Touraine JL
C R Acad Sci III; 1996 Sep; 319(9):789-98. PubMed ID: 8952882
[TBL] [Abstract][Full Text] [Related]
23. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
[TBL] [Abstract][Full Text] [Related]
24. Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules.
De Lerma Barbaro A; Sartoris S; Tosi G; Nicolis M; Accolla RS
J Immunol; 1994 Nov; 153(10):4530-8. PubMed ID: 7525708
[TBL] [Abstract][Full Text] [Related]
25. Molecular studies of a rare DR2/LD-5a/DQw3 HLA class II haplotype. Multiple genetic mechanisms in the generation of polymorphic HLA class II genes.
Liu CP; Bach FH; Wu SK
J Immunol; 1988 May; 140(10):3631-9. PubMed ID: 3129499
[TBL] [Abstract][Full Text] [Related]
26. Cell surface expression of hybrid murine/human MHC class II beta alpha dimers. Key influence of residues in the amino-terminal portion of the beta 1 domain.
Lechler RI; Sant AJ; Braunstein NS; Sekaly R; Long E; Germain RN
J Immunol; 1990 Jan; 144(1):329-33. PubMed ID: 2404065
[TBL] [Abstract][Full Text] [Related]
27. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency.
Durand B; Sperisen P; Emery P; Barras E; Zufferey M; Mach B; Reith W
EMBO J; 1997 Mar; 16(5):1045-55. PubMed ID: 9118943
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
29. Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA).
Patarroyo JC; Stuve O; Piskurich JF; Hauser SL; Oksenberg JR; Zamvil SS
Genes Immun; 2002 Feb; 3(1):34-7. PubMed ID: 11857059
[TBL] [Abstract][Full Text] [Related]
30. Characterisation of RT1-E2, a multigenic family of highly conserved rat non-classical MHC class I molecules initially identified in cells from immunoprivileged sites.
Lau P; Amadou C; Brun H; Rouillon V; McLaren F; Le Rolle AF; Graham M; Butcher GW; Joly E
BMC Immunol; 2003 Jul; 4():7. PubMed ID: 12837137
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
32. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants.
Chin KC; Li G; Ting JP
J Immunol; 1997 Sep; 159(6):2789-94. PubMed ID: 9300700
[TBL] [Abstract][Full Text] [Related]
33. Cooperativity between the J and S elements of class II major histocompatibility complex genes as enhancers in normal and class II-negative patient and mutant B cell lines.
Sugawara M; Scholl T; Mahanta SK; Ponath PD; Strominger JL
J Exp Med; 1995 Jul; 182(1):175-84. PubMed ID: 7790817
[TBL] [Abstract][Full Text] [Related]
34. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
[TBL] [Abstract][Full Text] [Related]
35. A binding protein to the DNase I hypersensitive site II in HLA-DR alpha gene was identified as NF90.
Sakamoto S; Morisawa K; Ota K; Nie J; Taniguchi T
Biochemistry; 1999 Mar; 38(11):3355-61. PubMed ID: 10079079
[TBL] [Abstract][Full Text] [Related]
36. Single base pair substitutions within the HLA-DRA gene promoter separate the functions of the X1 and X2 boxes.
Sloan JH; Hasegawa SL; Boss JM
J Immunol; 1992 Apr; 148(8):2591-9. PubMed ID: 1560213
[TBL] [Abstract][Full Text] [Related]
37. Mapping of the interaction site of the defective transcription factor in the class II major histocompatibility complex mutant cell line clone-13 to the divergent X2-box.
Ono SJ; Song Z
J Biol Chem; 1995 Mar; 270(11):6396-402. PubMed ID: 7890777
[TBL] [Abstract][Full Text] [Related]
38. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.
Wiszniewski W; Fondaneche MC; Louise-Plence P; Prochnicka-Chalufour A; Selz F; Picard C; Le Deist F; Eliaou JF; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2003 Feb; 54(11):747-55. PubMed ID: 12618906
[TBL] [Abstract][Full Text] [Related]
39. Defective HLA DRA X box binding in the class II transactive transcription factor mutant 6.1.6 and in cell lines from class II immunodeficient patients.
Stimac E; Urieli-Shoval S; Kempin S; Pious D
J Immunol; 1991 Jun; 146(12):4398-405. PubMed ID: 1904083
[TBL] [Abstract][Full Text] [Related]
40. The W element is a positive regulator of HLA-DRA transcription in various DR+ cell types.
Cogswell JP; Austin J; Ting JP
J Immunol; 1991 Feb; 146(4):1361-7. PubMed ID: 1991973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
